SG152279A1 - Interfering rna duplex having blunt-ends and 3æ-modifications - Google Patents

Interfering rna duplex having blunt-ends and 3æ-modifications

Info

Publication number
SG152279A1
SG152279A1 SG200902906-7A SG2009029067A SG152279A1 SG 152279 A1 SG152279 A1 SG 152279A1 SG 2009029067 A SG2009029067 A SG 2009029067A SG 152279 A1 SG152279 A1 SG 152279A1
Authority
SG
Singapore
Prior art keywords
blunt
modifications
interfering rna
rna duplex
duplex
Prior art date
Application number
SG200902906-7A
Other languages
English (en)
Inventor
Jan Weiler
Jonathan Hall
Jean-Charles Bologna
Francois Jean-Charles Natt
Robert Haener
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG152279A1 publication Critical patent/SG152279A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG200902906-7A 2003-08-28 2004-08-27 Interfering rna duplex having blunt-ends and 3æ-modifications SG152279A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49851403P 2003-08-28 2003-08-28

Publications (1)

Publication Number Publication Date
SG152279A1 true SG152279A1 (en) 2009-05-29

Family

ID=34272687

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200902906-7A SG152279A1 (en) 2003-08-28 2004-08-27 Interfering rna duplex having blunt-ends and 3æ-modifications

Country Status (21)

Country Link
US (2) US20070203084A1 (fr)
EP (3) EP2338995A3 (fr)
JP (2) JP2007503803A (fr)
KR (3) KR20060087531A (fr)
CN (2) CN101914533B (fr)
AU (1) AU2004269150C1 (fr)
BR (1) BRPI0413146A (fr)
CA (1) CA2536333C (fr)
CO (1) CO5680494A2 (fr)
EC (1) ECSP066388A (fr)
IL (1) IL173565A (fr)
IS (1) IS8358A (fr)
MA (1) MA28029A1 (fr)
MX (1) MXPA06002216A (fr)
NO (1) NO20061345L (fr)
NZ (1) NZ545360A (fr)
RU (2) RU2399671C2 (fr)
SG (1) SG152279A1 (fr)
TN (1) TNSN06065A1 (fr)
WO (1) WO2005021749A1 (fr)
ZA (1) ZA200601003B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413146A (pt) 2003-08-28 2006-10-03 Novartis Ag dúplex rna interferindo tendo extremidades-embotadas e modificações-3
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
JP5876637B2 (ja) * 2006-10-18 2016-03-02 マリーナ バイオテック，インコーポレイテッド ニックまたはギャップの入った核酸分子およびそれらの使用
JP4900943B2 (ja) * 2006-12-25 2012-03-21 独立行政法人産業技術総合研究所 ヌクレアーゼ耐性及びｒｎａ干渉効果に優れた修飾型二本鎖ｒｎａ
EP2319926B1 (fr) 2007-07-05 2016-08-31 Arrowhead Research Corporation ARNDB pour le traitement de l'infection virale
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
US20110311521A1 (en) 2009-03-06 2011-12-22 Pico Caroni Novel therapy for anxiety
EP2241323A1 (fr) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascine-W et cancers du cerveau
EP2292266A1 (fr) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Traitement du cancer en modulant la copine III
EP2480573A1 (fr) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Traitement du cancer par modulation de mex-3
WO2011045352A2 (fr) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Tyrosine kinase de la rate et cancers du cerveau
PL2509991T3 (pl) * 2009-12-09 2016-04-29 Nitto Denko Corp Modulacja ekspresji hsp47
AU2010332881B2 (en) 2009-12-18 2015-01-22 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat HSF1-related diseases
EP3721943A1 (fr) 2009-12-23 2020-10-14 Novartis AG Lipides, compositions de lipides et leurs procédés d'utilisation
CA2789125A1 (fr) 2010-02-10 2011-08-18 Novartis Ag Procedes et composes pour la croissance de muscle
EP2542578A1 (fr) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, ténascine-c et cancers du cerveau
WO2011131611A1 (fr) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulation de xrn1
WO2011133876A2 (fr) * 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucléotides comprenant des nucléosides acycliques et abasiques, et analogues
EP2561077B1 (fr) 2010-04-23 2016-04-13 Arrowhead Research Corporation Compositions organiques pour traiter des maladies associées à bêta-enac
EP2580239A1 (fr) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Traitement du cancer par modulation de la kinase 3 stérile de mammifère de type 20
WO2012168259A1 (fr) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protéine tyrosine phosphatase de type non-récepteur 11 (ptpn11), et cancer du sein triple négatif
WO2013010691A1 (fr) * 2011-07-18 2013-01-24 Devgen Nv Plantes résistantes aux insectes nuisibles
JP2014525435A (ja) 2011-09-02 2014-09-29 ノバルティス アーゲー Ｈｓｆ１関連疾患を処置するための有機組成物
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
EP2776022A1 (fr) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Traitement inédit contre les maladies neurodégénératives
EP2780017A1 (fr) 2011-11-15 2014-09-24 Novartis AG Combinaison d'un inhibiteur de la phosphoinositide 3-kinase et d'un modulateur de la voie janus kinase 2 - transducteur de signal et activateur de transcription 5
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
US10023862B2 (en) 2012-01-09 2018-07-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-catenin-related diseases
WO2013144240A1 (fr) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition de l'interleukine 8 et/ou de ses récepteurs cxcrl dans le traitement du cancer du sein surexprimant her2/her3
EA201492004A1 (ru) 2012-05-02 2015-08-31 Новартис Аг Органические композиции для лечения kras-ассоциированных заболеваний
DK2853597T3 (en) * 2012-05-22 2019-04-08 Olix Pharmaceuticals Inc RNA INTERFERENCE-INducing NUCLEIC ACID MOLECULES WITH CELL PENETENING EQUIPMENT AND USE THEREOF
US20150218238A1 (en) 2012-06-29 2015-08-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
WO2014006115A1 (fr) 2012-07-06 2014-01-09 Novartis Ag Combinaison d'un inhibiteur de phosphoinositide 3-kinase et d'un inhibiteur de l'interaction il-8/cxcr
US9868949B2 (en) 2013-02-28 2018-01-16 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat EPAS1-related diseases
KR102144777B1 (ko) * 2013-06-19 2020-08-18 제이더블유중외제약 주식회사 결정형 메로페넴 삼수화물의 제조방법
EP3030902B1 (fr) 2013-08-07 2019-09-25 Friedrich Miescher Institute for Biomedical Research Nouveau procédé de criblage pour traiter l'ataxie de friedreich
WO2015051135A2 (fr) 2013-10-04 2015-04-09 Novartis Ag Compositions organiques destinées au traitement de maladies associées à l'hepcidine
WO2015051044A2 (fr) 2013-10-04 2015-04-09 Novartis Ag Formats inédits pour composés organiques utiisables en interférence arn
EP3052107B1 (fr) 2013-10-04 2018-05-02 Novartis AG Composés organiques destinés au traitement du virus de l'hépatite b
EP3052464B1 (fr) 2013-10-04 2020-04-15 Novartis AG 3'end caps pour des agents arni utilisés dans l'interférence d'arn
EP3052627B1 (fr) 2013-10-04 2018-08-22 Novartis AG Formats inédits pour composés organiques utilisables en interférence arn
KR101696704B1 (ko) * 2013-12-17 2017-01-16 주식회사 인코드젠 오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도
US20170137824A1 (en) 2014-06-13 2017-05-18 Indranil BANERJEE New treatment against influenza virus
EP3164129A1 (fr) 2014-07-01 2017-05-10 Friedrich Miescher Institute for Biomedical Research Combinaison d'un inhibiteur de braf v600e et d'un inhibiteur de mertk pour le traitement du mélanome
WO2016011123A1 (fr) 2014-07-16 2016-01-21 Arrowhead Research Corporation Compositions organiques pour letraitement de pathologies liées à l'apoc3
US10342761B2 (en) 2014-07-16 2019-07-09 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
WO2016038550A1 (fr) 2014-09-11 2016-03-17 Novartis Ag Inhibition de prmt5 dans le traitement de maladies liées à une déficience en mtap
US20170298360A1 (en) 2014-09-24 2017-10-19 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
US10479997B2 (en) 2014-12-01 2019-11-19 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
EP3302525A2 (fr) 2015-06-05 2018-04-11 Novartis AG Méthodes et compositions permettant de diagnostiquer, traiter et surveiller le traitement de troubles associés à une déficience en shank3
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
JOP20200228A1 (ar) 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
US9721645B1 (en) 2016-01-29 2017-08-01 Taiwan Semiconductor Manufacturing Company, Ltd. SRAM arrays and methods of manufacturing same
WO2018047148A1 (fr) 2016-09-12 2018-03-15 Novartis Ag Composés pour inhibition du miarn
WO2018083606A1 (fr) 2016-11-01 2018-05-11 Novartis Ag Procédés et compositions pour améliorer l'édition de gènes
EP4085919A3 (fr) 2017-07-21 2023-02-08 Novartis AG Compositions et procédés permettant de traiter un cancer
TN2020000039A1 (en) 2017-09-11 2021-10-04 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
EP3788138A1 (fr) 2018-05-02 2021-03-10 Novartis AG Régulateurs de cellules souches pluripotentes humaines et leurs utilisations
WO2024134505A1 (fr) 2022-12-20 2024-06-27 Novartis Ag Procédé de ligature d'acide nucléique
WO2024134502A1 (fr) 2022-12-20 2024-06-27 Novartis Ag Ligases d'arn double brin modifiées et leurs utilisations

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658562B2 (en) * 1989-10-24 1995-04-27 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US6399754B1 (en) * 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US5670633A (en) * 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US6005087A (en) * 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US6033909A (en) * 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
NZ245720A (en) 1992-01-22 1995-12-21 Hoechst Ag Oligonucleotide analogues; use as gene expression inhibitor or dna probe
CA2222328C (fr) * 1995-06-07 2012-01-10 Inex Pharmaceuticals Corporation Particules d'acides nucleiques et de lipides preparees au moyen d'un intermediaire de complexe hydrophobe d'acides nucleiques et de lipides et utilisation pour transferer des genes
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6287591B1 (en) * 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6211349B1 (en) * 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
CA2361201A1 (fr) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition et methode destinees a l'attenuation in vivo et in vitro de l'expression genique utilisant de l'arn double brin
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US20050233329A1 (en) * 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. Inhibition of gene expression using duplex forming oligonucleotides
WO2003070918A2 (fr) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Inhibition mediee par interference arn d'une expression genique faisant appel a des acides nucleiques interferants courts chimiquement modifies (sina)
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
US20030190635A1 (en) 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
BRPI0115814B8 (pt) * 2000-12-01 2021-05-25 Europaeisches Laboratorium Fuer Molekularbiologie Embl moléculas de rna de filamento duplo, seu método de preparação e composição farmacêutica compreendendo as mesmas
US20020132257A1 (en) * 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US20040019001A1 (en) * 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20070032441A1 (en) * 2001-05-18 2007-02-08 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
CA2526831C (fr) 2001-05-18 2012-07-31 Sirna Therapeutics, Inc. Interference arn a mediation assuree par l'inhibition de genes au moyen de petit acide nucleique interferent (ansi) modifie chimiquement
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
AU2002344237B8 (en) * 2001-05-29 2008-11-06 Sirna Therapeutics, Inc. Nucleic Acid Based Modulation of Female Reproductive Diseases and Conditions
US20090247606A1 (en) * 2001-08-28 2009-10-01 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP1432724A4 (fr) 2002-02-20 2006-02-01 Sirna Therapeutics Inc Inhibition a mediation par interference d'arn de genes de map kinase
US8258288B2 (en) * 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
ES2280826T5 (es) * 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
EP1389637B1 (fr) * 2002-08-05 2012-05-30 Silence Therapeutics Aktiengesellschaft Molécules d'ARN interférant à bords francs
JP4605799B2 (ja) * 2003-04-02 2011-01-05 ダーマコン， インコーポレイテッド Ｒｎａ干渉において使用するための修飾ポリヌクレオチド
WO2004092383A2 (fr) * 2003-04-15 2004-10-28 Sirna Therapeutics, Inc. Inhibition par interference d'arn de l'expression genetique virale du syndrome respiratoire aigu severe au moyen d'acide nucleique d'interference court
EP1620544B1 (fr) * 2003-04-17 2018-09-19 Alnylam Pharmaceuticals Inc. Agents modifies d'arni
WO2005009346A2 (fr) * 2003-06-24 2005-02-03 Mirus Corporation Inhibition d'une fonction genique par distribution in vivo d'inhibiteurs d'expression genique a base de polynucleotides dans des cellules mammiferes
BRPI0413146A (pt) 2003-08-28 2006-10-03 Novartis Ag dúplex rna interferindo tendo extremidades-embotadas e modificações-3
WO2005115481A2 (fr) 2004-05-27 2005-12-08 Alnylam Pharmaceuticals, Inc. Acide ribonucleique double brin resistant aux nucleases
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR101059315B1 (ko) 2011-08-24
JP2011160796A (ja) 2011-08-25
KR20080034046A (ko) 2008-04-17
RU2399671C2 (ru) 2010-09-20
CN101914533A (zh) 2010-12-15
RU2010119292A (ru) 2011-12-10
ECSP066388A (es) 2006-08-30
IL173565A (en) 2012-07-31
US20090192113A1 (en) 2009-07-30
CO5680494A2 (es) 2006-09-29
AU2004269150C1 (en) 2010-11-18
IL173565A0 (en) 2006-07-05
KR20060087531A (ko) 2006-08-02
AU2004269150A1 (en) 2005-03-10
CA2536333A1 (fr) 2005-03-10
JP2007503803A (ja) 2007-03-01
US20070203084A1 (en) 2007-08-30
CN1845993B (zh) 2010-06-23
US8097716B2 (en) 2012-01-17
WO2005021749A1 (fr) 2005-03-10
EP1660657A1 (fr) 2006-05-31
CN1845993A (zh) 2006-10-11
CN101914533B (zh) 2013-06-19
MXPA06002216A (es) 2006-04-27
ZA200601003B (en) 2007-04-25
RU2006109547A (ru) 2007-10-10
IS8358A (is) 2006-03-17
EP2338995A2 (fr) 2011-06-29
NO20061345L (no) 2006-05-29
EP2338995A3 (fr) 2012-01-11
TNSN06065A1 (en) 2007-10-03
BRPI0413146A (pt) 2006-10-03
AU2004269150B2 (en) 2009-06-04
CA2536333C (fr) 2013-01-08
KR20110007263A (ko) 2011-01-21
EP2489737A1 (fr) 2012-08-22
NZ545360A (en) 2009-06-26
MA28029A1 (fr) 2006-07-03

Similar Documents

Publication Publication Date Title
SG152279A1 (en) Interfering rna duplex having blunt-ends and 3æ-modifications
EP1323034A4 (fr) Metamodele d'application commun dont le metamodele c/c++
MXPA03005769A (es) Politrimetilen eter ester amida y uso de la misma.
EP1463742A4 (fr) Nouvelles pyrazolo-pyrimidines et pyrrolo-pyrimidines et leur utilisation
JO2410B1 (en) 6. Replaced pyrido-pyrimidines
EP1453837A4 (fr) Agents therapeutiques cibles et leurs utilisations
EP1408978A4 (fr) Nouvelles phenylamino-pyrimidines et leur utilisation
AU2002362132A8 (en) Biological defense masks
GB2376928B (en) Personal hoverplane having four tiltmotors
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
HUP0402301A2 (en) Protective clothing against biological agents
EP1408985A4 (fr) Nouveaux pyridopyrimidones et leurs utilisations
GB2398493B (en) Hairdresser's masking aid
EP1279872A4 (fr) Petit instrument portatif
HU0103040D0 (en) High - level source and it's application
DE60207900D1 (de) "Suspend"-Paketübertrager
GB2385023B (en) Portable desk or lectern
FR2860405B1 (fr) Comptoir d'accueil
AU146906S (en) Desk set
ZA200507393B (en) Hairdresser's masking aid
TW534416U (en) Improved structure of name card clip
GB2397802B (en) Portable desk or lectern
UA5051S (uk) Емблема «wrangler»
UA6121S (uk) Емблема «джерело»
CA97136S (en) Personal scale